In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
BUSINESS
Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
Johnson & Johnson’s Janssen Japan unit will make inroads into the lung cancer market, with a recently filed EGFR-targeted combination therapy expected to be its first product in this arena if approved. Kiran Patel, vice president of clinical development, solid…
To read the full story
Related Article
BUSINESS
- FDA Approves Izervay’s Wider Label with No Dosing Duration Limit
February 14, 2025
- Susmed to Get 100 Million Yen Milestone after PMS App Trial Start
February 13, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Meiji Logs Operating Loss in Vaccine Biz on Kostaive Devaluation
February 12, 2025
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…